Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DTG/ABC/3TC FDC in Acute HIV Infection
NCT02384395Completed
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Sep 2015
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of dolutegravir in acute human immunodeficiency virus infection, sponsored by University of North Carolina at Chapel Hill. Primary endpoint: Number of Participants With Viral Load Measurement <200 Copies/mL at 24 weeks. Started Sep 2015; status: completed.
02
Drugs
dolutegravir
03
Conditions
acute human immunodeficiency virus infection
Beyond the preview
Go deeper on NCT02384395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02384395.